All In Biotech

Drug Trial Radar · NCT02531802

Enterotoxigenic Escherichia Coli (ETEC) ETVAX Vaccine Trial in Bangladesh

A Randomized, Double-blind, Placebo-controlled, Dose-Escalation Study Evaluating the Safety, Tolerability, and Immunogenicity of an Oral Inactivated ETEC Vaccine (ETVAX) Alone and Together With dmLT Adjuvant in Descending Age Groups in Bangladesh

Last checked: Nov 20, 2026Latest source record: Sep 12, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 475 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

475

Actual

Start

Oct 2015

Primary completion

Jul 29, 2017

Study completion Jul 29, 2017

Sponsor

Lead sponsor
PATHAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Scandinavian Biopharma AB; International Centre for Diarrhoeal Disease Research, Bangladesh
First posted
Aug 24, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 6 months, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine if the ETEC vaccine ETVAX with and without dmLT adjuvant is safe and immunogenic in adults, children, toddlers and infants in Bangladesh.

Conditions

  • Escherichia Coli Diarrhea

Interventions

  • ETVAXBiological

    Varying dosages of liquid ETVAX vaccine (Batch BX1003574). A full dose consisted of: * Hybrid protein between the B-subunit of the E. coli heat-labile enterotoxin and the B-subunit of the cholera toxin (LCTBA): 1 mg * E. coli ETEX 21 formalin inactivated: 1.3 mg colonization factor 1 (CFA/I) * E. coli ETEX 22 formalin inactivated: 6.4 mg coli surface antigen 3 (CS3) * E. coli ETEX 23 formalin inactivated: 1.1 mg coli surface antigen 5 (CS5) * E. coli ETEX 24 phenol inactivated: 0.5 mg coli surface antigen 6 (CS6) The vaccine was given together with sodium bicarbonate effervescent granules (Recip), which was dissolved in water and mixed with the vaccine suspension prior to oral administration. The buffer was used to prevent degradation of LCTBA hybrid protein by the gastric acid.

  • dmLTBiological

    Varying dosages of dmLT, a derivative of wild-type enterotoxigenic Escherichia coli LT that has been genetically modified by replacing the arginine at amino acid position 192 with glycine and the leucine at amino acid position 211 with alanine. These two amino acid substitutions take place in proteolytic cleavage sites which are critical for activation of the secreted toxin molecules.

  • Bicarbonate BufferOther

    Sodium bicarbonate buffer dissolved in 150 ml of potable water

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number and Percentage of Participants Experiencing Solicited Events by Symptom and Maximum SeverityTime frame: 7 days after each vaccination (Day 7 and Day 21)
  2. Number and Percentage of Participants Experiencing Unsolicited Adverse Events Related to VaccineTime frame: 6 months ± 14 days after the first dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • International Centre for Diarrheal Disease, Bangladesh (icddr,b)

    Dhaka, Bangladesh

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.